CYduct Diagnostics, Inc. engages in the development and marketing of technology, applications, medical devices, and procedural techniques for screening, diagnosis, treatment, and management of disease and medical conditions. The company is headquartered in Westport, Connecticut. The company went IPO on 2001-06-21. The firm focuses on the women's healthcare market, primarily breast healthcare and wellness. The company is focused on breast health and wellness through testing methods. The company focuses to provide a technology platform that includes evidence-based personalized breast health risk assessment testing. The firm serves medical schools, hospitals and physicians to develop medical devices and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.
최신 재무제표(Form-10K)에 따르면, Digital China Holdings Limited의 총 자산은 $0이며, 순손실입니다.
CYDX의 주요 재무 비율은 무엇인가요?
Digital China Holdings Limited의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Cyduct Diagnostics Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Digital China Holdings Limited 주요 수익원은 Traditional and Localization Services이며, 최신 수익 발표에서 수익은 7,943,290,000입니다. 지역별로는 China이 Digital China Holdings Limited의 주요 시장이며, 수익은 16,657,343,000입니다.
Cyduct Diagnostics Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Digital China Holdings Limited의 순손실은 $0입니다.